TD Cowen raised the firm’s price target on Regeneron to $1000 from $900 and keeps an Outperform rating on the shares. The firm said Eylea HD should beat Vabysmo every quarter, and the pricing reset is underappreciated. They also noted the Eylea focus distracts from Dupi’s growth, which drives the majority of earnings.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron price target raised to $937 from $935 at Jefferies
- Regeneron, Sanofi report Dupixent reduced COPD exacerbations in second trial
- Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
- Regeneron Announces Investor Conference Presentation
- Regeneron commits $34M over five years to sponsor science & engineering fair